PerkinElmer has appointed Neil Cook as chief scientific officer for PerkinElmer Life Sciences and as the company’s overall vice president of global research & development. Cook will report to John Engel, president of PerkinElmer Life Sciences and executive vice president of PerkinElmer.
He will be responsible for the global integration of the company’s life sciences R&D efforts and for guiding the company’s technology development efforts, which have expanded in the wake of PerkinElmer’s November acquisition of Packard Biosciences.
Cook comes to PerkinElmer after 15 years at Amersham Biosciences, where he most recently served as vice president of corporate development. He previously was Amersham’s senior vice president of drug discovery, heading up the company’s genomics, proteomics, drug discovery, and bioinformatics areas. Cook received his PhD in biochemistry from the University of London, Kings College, and has completed post-doctoral training in cancer research at the Clinical Research Center in the UK.
Meanwhile, Cook’s previous employer, Amersham Biosciences, has appointed Trevor Hawkins, formerly director of the US Department of Energy’s Joint Genome Institute, as senior vice president of genomics. Hawkins will head up Amersham’s genomics strategy from the company’s Sunnyvale, Calif., office, and will report to Amersham Biosciences’ CEO Andrew Carr.
Hawkins joined the JGI in 1999, and previously served as CuraGen’s vice president of Genomics. He obtained a PhD in biochemistry from the University of Sussex in 1993.
Redmond, Wash., microfluidics startup Micronics has appointed Steve Gailar as its chief executive officer and chairman, replacing Jim Marselis. Karen Hedine, formerly the company’s vice president of business development, is the new president and a director; and Fred Battrell is the company’s vice president of operations. The company also appointed three members to its board, including Marselis.
SRI International, which has recently begun developing microarray analysis software packages, has transferred Michael Tracy, the vice president of the pharmaceutical discovery division, as its new vice president for corporate business development in biotechnology. In this role, Tracy will also join the company’s new ventures and strategic business development team.